Dr. Abdel-Azim is a distinguished pediatric hematologist/oncologist. He currently holds various academic, clinical and research appointments at Loma Linda University School of Medicine and Children Hospital and Medical Center, Loma Linda, CA. He serves as:

• Chief for the Division of Transplant and Cell Therapy/Hematological Malignancies, Cancer Center, Loma Linda University School of Medicine, Children Hospital and Medical Center
• Director of the Combined Adult and Pediatric, Transplant and Cell Therapy program, TCT-GMP Lab (Transplant and Cell Therapy- Good Manufacturing Practice Laboratory) and Leukemia research Program, Loma Linda University School of Medicine, Children Hospital and Medical Center
• Professor of Pediatrics, Medicine and Basic Sciences, Loma Linda University School of Medicine
• Director, Blood and Marrow Transplant (BMT) Fellowship Program, Children’s Hospital Los Angeles, Los Angeles, CA

His major areas of research interest include minimal residual disease in hematological malignancies, non-TBI based conditioning for acute lymphoblastic leukemia, use of cell and immune therapy for treatment of acute leukemia in children as well as Bone Marrow Transplantation for hemoglobinopathies and genetic diseases and Treatment of Graft versus Host Disease (GVHD).

Dr. Abdel-Azim is a principal investigator on numerous clinical trials and has authored over 130 peer-reviewed publications. He is a member/fellow of children oncology protocol committees and various societies including ASH, ASCO, ASGT, ASPHO and CCS.

He completed his medical education and early training at Cairo University, followed by residency at New York Medical College and fellowships in pediatric hematology/oncology and stem cell transplantation at Children’s Hospital Los Angeles/USC.

Ali is a founding team member and leads all clinical matters for Summer Health, a pediatric health tech company revolutionizing access to care for children and families. Prior to Summer Health, Ali was a clinical strategy executive at Humana. He also worked at Boston Consulting Group where he led projects across biopharma, med tech, payors, and federal government. Ali is also on staff as a hospitalist at Boston Children’s Hospital, where he completed his pediatric training. He received his bachelor’s from MIT and medical degree from Harvard Medical School. He also holds a Master’s of Science in health policy from the London School of Economics, where he was a Marshall Scholar.

Dr. Stephanie Baskin was born and raised in the suburbs of Dallas, TX. She attended college at Texas A&M University and medical school at John P. and Kathrine G. McGovern Medical School at UTHealth, formerly known as The University of Texas Medical School at Houston. She stayed at McGovern Medical School to complete her combined pediatrics and medical genetics residency. She joined the faculty of Baylor College of Medicine at CHRISTUS Children’s Hospital in San Antonio in early 2021 and serves as an assistant professor of pediatrics and molecular and human genetics. Dr. Baskin is particularly interested in determining the molecular underpinnings of vascular anomalies as a means to determining targeted therapies for an often challenging to manage disease process. She is passionate about walking alongside patients and families as they journey through their diagnostic odyssey with genetics. When not working, she enjoys spending time with her husband and four children, serving in her church, and cheering on the Texas A&M Aggies.

Michael Faithe is a pharmacist and a Director on the Payer, Value, and Outcomes team at Jazz Pharmaceuticals. He provides clinical and health economic information to health care providers and formulary decision makers at health systems and regional and national payers across the Jazz Neuroscience and Oncology portfolio.

Prior to Jazz he worked at Amgen in a similar role and was responsible for providing clinical and health economic information to formulary decision makers and health systems for both regional and national payer accounts.

Prior to industry, Michael worked as an inpatient Clinical Pharmacy Specialist in
Neurosciences at the University of Colorado Hospital in Aurora, CO. He was involved in the clinical care of patients with epilepsy, stroke, neurosurgery, and other acute and chronic neurological disorders.

He currently resides with his wife and two kids (7 and 3) in beautiful Grand Junction, CO where he enjoys a large variety of outdoor recreational activities including: mountain biking, yoga, golf, cross country skiing, and camping.

Jake Galdo is CEO of Seguridad. Seguridad develops and implements quality measures in the Choose My Pharmacy measurement system. As the national standard for community pharmacy quality, Choose My Pharmacy is used for quality improvement, value-based contracts, and patient engagement.

Additionally, Dr. Galdo is the Managing Network Facilitator for CPESN® Community Health, a clinically integrated network of community pharmacies focused on addressing health-related disparities. As the network lead, he consultants on the delivery health equity services, practice transformation to local communities, and advancement of community pharmacies, pharmacists, and pharmacy technicians.

He also spends his professional time staffing in a neighborhood community pharmacy, developing innovative clinical services, and representing the profession of pharmacy on various boards and advisory committees for regional and national organizations.

Dr. Galdo is extensively published in the peer and non-peer reviewed literature, including JAPhA, WIRED, and the Wall Street Journal. He has previous experiences in association management, quality measure development, continuing education, academia, clinical trial recruitment, and community pharmacy practice. He received his Doctor of Pharmacy and completed PGY-1 Community Pharmacy Residency training from the University of Georgia, earned a Master of Business Administration from Samford University, and is board certified in both pharmacotherapy and geriatrics. Dr. Galdo lives in Birmingham, AL with wife, daughter, dad, and a pack of pets.

Michael Lunzer is the Founder and CEO of Itiliti Health, Inc., where he drives innovation in healthcare by streamlining and automating prior authorization. A seasoned entrepreneur, Michael co-founded the first-ever technology-based vendor management system for the staffing industry, which processed $2 billion annually by 2005. He also co-founded Warm Health, a virtual care manager platform for payers, later acquired by Change Healthcare. With a career focused on solving inefficiencies through technology, Michael continues to lead transformative change in healthcare, making him a sought-after speaker on industry innovation and optimization.

Marjan is an accomplished Medical Affairs professional with over two decades of experience. Marjan received her Bachelor of Science in Biology from the University of South Carolina in 1994, and her Doctorate in Pharmacy (PharmD) at Mercer University Southern School of Pharmacy in 2002. She completed an accredited Managed Care Practice Residency at Walgreens Health Initiatives (a pharmacy benefit management subsidiary of Walgreens) in 2003. Upon completion of her formal education and residency, she has worked in various roles within pharmacy benefits management as a data analyst and clinical program manager (2003-2005) before joining the pharmaceutical industry (2005-current). For the past 20 years and within her current role at BeOne Medicines, Marjan’s roles and responsibilities have largely included establishing and maintaining scientifically credible peer-to-peer scientific relationships with national and regional payers and population health decision makers, communicating and presenting clinical and health economics/outcomes research (HEOR) data, and assisting with real world evidence, including collaborating with key external stakeholders, supporting development of key endpoints or outcomes, drafting protocols for observational projects, and co-authoring publications. She has also supported various brands and investigational compounds for pipeline presentations, pre-approval information exchange (PIE), product launches and provided strategic/tactical payer and institution account support primarily within oncology, urology and diabetes therapeutic areas. Her current experience at BeOne Medicines has also focused on clinical & real world evidence needs of an oncology/hematology portfolio.